RxDoctor Payments Data

Jeremy Smith, MD

Internal Medicine · Birmingham, ALNPI 1558574715

Payments from drug & device makers

$1,161in general payments, 2019–2025

Across 67 payments — averaging $17.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$258
  • Pfizer$160
  • GSK$153
  • Dexcom, Inc.$107
  • Amgen$58
  • Johnson & Johnson$43
  • plus $383 from 17 others

What the payments were for

  • Food & beverage$1,15599%
  • Education$61%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,161 in reported general payments places this provider in the 60th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$314,861
Medicare patients
351
Services billed
15,950

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban453$433,666
OzempicSemaglutide154$173,227
FarxigaDapagliflozin Propanediol105$117,519
MounjaroTirzepatide102$112,370
JardianceEmpagliflozin91$106,777
GlyxambiEmpagliflozin/Linagliptin63$76,205
Trelegy ElliptaFluticasone/Umeclidin/Vilanter64$51,863
XareltoRivaroxaban40$44,149
JanuviaSitagliptin Phosphate66$36,567
EntrestoSacubitril/Valsartan41$31,697
RybelsusSemaglutide17$28,059
RexultiBrexpiprazole17$20,279
Repatha SureclickEvolocumab31$17,602
Breo ElliptaFluticasone/Vilanterol27$14,156
MyrbetriqMirabegron13$13,760

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$160$433,666453 claims
Novo NordiskOzempic, Rybelsus$41$201,287171 claims
Boehringer IngelheimJardiance, Glyxambi, Synjardy Xr$39$195,313171 claims
AstraZenecaFarxiga, Brilinta$258$122,844117 claims
Lilly USA, LLCMounjaro$11$112,370102 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$153$77,004109 claims
Johnson & JohnsonXarelto$43$44,14940 claims
Astellas Pharma US IncMyrbetriq$31$13,76013 claims
AbbVieSynthroid$38$4,27656 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →